# Siren Care

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/siren-care

- Industry: Healthcare IT
- Headquarters: San Francisco, US
- Website: www.siren.care
- Total disclosed funding: $24M
- Latest round: Series B (Oct 1, 2020)
- Investors on record: 11

## About

Siren Care, Inc. is a US-based manufacturer specializing in innovative diabetic care solutions that includes smart socks for continuous temperature monitoring to prevent foot ulcers in individuals with diabetes.Siren Care, Inc. develops advanced healthcare products aimed at preventing diabetic foot complications. Founded in 2016 and headquartered in San Francisco, US, the company has raised a total of USD 9.5 mn through a Series B funding round in January 2025, led by Mölnlycke Health Care AB. The company's founding team includes Diego Vitale, Henk Scholten, Jie Fu, and CEO Ran Ma. The latest deal marks significant progress in their funding journey, with a total of 7 deals recorded.Siren Care offers Siren Socks, specially designed to protect diabetes patients from foot ulcers through continuous temperature monitoring. These socks provide real-time data that can indicate potential injuries or inflammation, reducing ulcer risks for over 30% of individuals with diabetes. The product is crucial for patients requiring diligent foot care management and is marketed primarily to individuals with diabetes and healthcare providers.Siren Care generates revenue through a subscription model, where clients receive both the Siren Socks and associated monitoring services. Healthcare providers, such as nurses and podiatrists, play an essential role in utilizing the sock data to monitor patient health. The business model supports direct-to-consumer sales, allowing patients to access the socks and ongoing health monitoring directly. Costs are covered by Medicare, ensuring affordable long-term care solutions for patients at risk of diabetic foot ulcers.In January 2025, Siren Care, Inc. raised USD 9.5 mn in Series B funding, which will be utilized to enhance and develop its healthcare platform. The company is focused on expanding its product offerings and aims to enter new geographic markets, although specific regions have not been disclosed. Upcoming product launches are anticipated to broaden their impact on diabetic care.

## Funding rounds

- Series B, Oct 1, 2020, $9M — DCM, Founders Fund, Khosla Ventures, 500 Global, Portfolia, Mighty Capital, Manta Ray Ventures, Aloft VC
- Series B, May 27, 2020, $12M — DCM, Founders Fund, Khosla Ventures, 500 Global, Aloft VC
- Seed, Mar 28, 2018, $3.4M — DCM, Founders Fund, Khosla Ventures, Liquid 2 Ventures
- Seed, Mar 1, 2017 — Plug and Play, A-Level Capital

## Investors

- Plug and Play (https://capitalatlas.ai/funds/plug-and-play) — Seed
- A-Level Capital (https://capitalatlas.ai/funds/a-level-capital) — Seed
- DCM (https://capitalatlas.ai/funds/dcm) — Seed, Series B
- Founders Fund (https://capitalatlas.ai/funds/founders-fund) — Seed, Series B
- Khosla Ventures (https://capitalatlas.ai/funds/khosla-ventures) — Seed, Series B
- Liquid 2 Ventures (https://capitalatlas.ai/funds/liquid-2-ventures) — Seed
- 500 Global (https://capitalatlas.ai/funds/500-global) — Series B
- Aloft VC (https://capitalatlas.ai/funds/aloft-vc) — Series B
- Portfolia (https://capitalatlas.ai/funds/portfolia) — Series B
- Mighty Capital (https://capitalatlas.ai/funds/mighty-capital) — Series B
- Manta Ray Ventures (https://capitalatlas.ai/funds/manta-ray-ventures) — Series B